This randomized controlled trial investigated the treatment satisfaction of men with erectile dysfunction (ED) and their partners after switching from on-demand phosphodiesterase type 5 (PDE5) inhibitors to a daily regimen of tadalafil 5 mg. The study included men aged 18 and older with a history of ED who had been
